2022 RT Banner.gif

China Daily

News> Nation> Content
Published: 15:30, December 09, 2021 | Updated: 15:37, December 09, 2021
Two Chinese COVID medicines receive emergency approval
By Xinhua
Published:15:30, December 09, 2021 Updated:15:37, December 09, 2021 By Xinhua

This undated photo shows two employees working in a drug research and development laboratory in Dongguan, Guangdong province. (ZHAN YOUBING / FOR CHINA DAILY)

BEIJING - The National Medical Products Administration has given emergency approval to the registration application of two COVID-19 medicines, BRII-196 and BRII-198.

The two medicines are used in combination to treat adult and adolescent patients with mild and moderate symptoms and with severe risk factors for progression, according to the NMPA 

This is China's first approved COVID-19 virus-neutralizing antibody combination therapy with independent intellectual property rights.

The two medicines are used in combination to treat adult and adolescent patients with mild and moderate symptoms and with severe risk factors for progression, according to the NMPA. Specifically, the medicines are conditionally approved for adolescents ranging from 12 to 17 years of age with a body weight greater than 40 kg.

READ MORE: 2 Chinese anti-COVID-19 drug candidates in clinical trials

Tsinghua University, the Third People's Hospital of Shenzhen and Brii Biosciences have jointly developed the cocktail therapy of monoclonal antibodies BRII-196 and BRII-198, which are derived from antibodies isolated from people who have recovered from COVID-19.


Share this story

CHINA DAILY
HONG KONG NEWS
OPEN
Please click in the upper right corner to open it in your browser !